Provided are azetidine cyclic urea compounds that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.
Selective mono- and bis-sulfenylation of activemethylene groups with a variety of disulfides at an ambient temperature is reported. Sulfenylation is promoted by iodine as a catalyst and sulfenyl iodides as intermediates, under metal-free conditions. The method is greener in terms of solvent selection and the use of less hazardous DMSO as an oxidant. The procedure is highly efficient with readily available